To Evalute the Analgesic effect of Coenzyme Q10 in Acute Herpes Zoster

Evaluate pain ameliorating effect of Coenzyme Q10 in Acute Herpes Zoster - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055198

Enrollment

Registered

2023-07-13

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B022- Zoster with other nervous system involvement

Interventions

Intervention1: Coenzyme Q10: Coenzyme Q10 (100mg) given daily for 4 weeks VAS SCORE assessed for 1 month. Intervention2: COENZYME Q10: At 0 week VAS Score will be assessed then COENZYME Q10 (100mg) wi

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade 1 AND 2

Exclusion criteria

Exclusion criteria: pregnancy thyroid diabetes liver or renal disease immunocompromised patient

Design outcomes

Primary

Measure	Time frame
Evalute the ameliorating effect of Coenzyme Q10 in Acute Herpes ZosterTimepoint: VAS Score will be assessed at 0, 2 and 4 weeks	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Nada Habib Ur Rehman

Pt BD Sharma PGIMS Rohtak

nadahabib24@gmail.com8377044715

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026